Pharmaceuticals & Medical Research

0.001

0.000-0.55%

Number of Gainers:1

Number of Losers:2

Number of Flat:3

PE:- -

High:0.001

Open:0.001

Low:0.001

Close:0.001

Loading ...

Overview News

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK6506/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK6506","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK6506\",,,,,undefined,":{"symbol":"BK6506","market":"SI","secType":"PLATE","nameCN":"Pharmaceuticals & Medical Research","latestPrice":0.0011373047,"timestamp":1749182359454,"preClose":0.0011436349,"halted":0,"volume":1284800,"delay":0,"changeRate":-0.005535,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Noon Closed","change":-0.000006,"latestTime":"06-06 12:00:00 SGT","open":0.0011430436,"high":0.0011430436,"low":0.0011343482,"amount":2419869.8,"amplitude":0.007603,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749186000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749169800000,1749182400000],[1749186000000,1749201360000]],"pbRate":1.197034,"peRate":10.900855,"turnoverRate":0.001091,"increases":1,"decrements":2,"flats":4,"marketCap":4593774703.5,"floatMarketCap":2688522167.125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK6506\",,,,,undefined,":{"symbol":"BK6506","high":0.0011430436,"amplitude":0.007603,"preClose":0.0011436349,"low":0.0011343482,"pbRate":"1.197034","latestPrice":0.0011373047,"volume":1284800,"delay":0,"open":0.0011430436,"prevYearClose":0.02811279,"prevWeekClose":0.0011,"prevMonthClose":0.0011,"prevQuarterClose":0.0103,"fiveDayClose":0.0011,"twentyDayClose":0.0011,"sixtyDayClose":0.0099,"secType":"PLATE","market":"SI","turnoverRate":0.001091,"peRate":10.900855,"marketCap":4593774703.5,"floatMarketCap":2688522167.125,"timestamp":1749182359454,"nameCN":"Pharmaceuticals & Medical Research"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK6506\",,,,undefined,":{"bkCode":"BK6506","up":1,"down":2,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK6506\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534296723","title":"Hyphens Pharma Further Increases Stake in Ardence Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2534296723","media":"MT Newswires","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534296723?lang=en_us&edition=fundamental","pubTime":"2025-05-12 13:48","pubTimestamp":1747028913,"startTime":"0","endTime":"0","summary":"Hyphens Pharma  completed the proposed acquisition of tranche 2 sale shares of Ardence Pharma for a total consideration of 10.9 million ringgit, according to a filing with the Singapore Exchange on Friday.Following the completion of the tranche 2, the company now has an 82% stake in Ardence, a Malaysia-based boutique pharmaceutical company specializing in aesthetic medicine.In an earlier filing, the company, through its unit Hyphens Pharma, agreed to acquire the remaining 58% stake in Ardence Pharma in three tranches.Under first tranche, the pharmaceutical company acquired 23% of Ardence Pharma for 6.4 million Malaysian ringgit.In the second and third tranches, Hyphens Pharma will acquire 17% and 18% of Ardence Pharma, respectively, at an amount mutually agreed between the parties involved.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["1J5.SI","BK6506","BK6079"],"gpt_icon":0},{"id":"2534255711","title":"Lonza Reports Strong Performance in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2534255711","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534255711?lang=en_us&edition=fundamental","pubTime":"2025-05-09 14:55","pubTimestamp":1746773711,"startTime":"0","endTime":"0","summary":"Lonza  posted strong performances across its CDMO business division during the first quarter of the year, according to a filing with the Singapore Exchange on Friday.The Biologics segment showcased great momentum due to solid showing in the Mammalian and Bioconjugates divisions.There was also a strong demand from the Cell & Gene division.In its Outlook 2025, the pharmaceutical company expects 20% sales growth and a core EBITDA margin of about 30%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6506","O6Z.SI"],"gpt_icon":0},{"id":"2531723884","title":"Tianjin Pharmaceutical Da Ren Tang Attributable Profit Shrinks in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2531723884","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531723884?lang=en_us&edition=fundamental","pubTime":"2025-04-30 10:25","pubTimestamp":1745979940,"startTime":"0","endTime":"0","summary":"Tianjin Pharmaceutical Da Ren Tang's  net profit attributable to owners of the parent declined 3% during the first quarter of the year to 374.2 million yuan from 387.3 million yuan a year earlier, according to a filing with the Singapore Exchange on Tuesday.Earnings per share dropped to 0.49 yuan compared with 0.50 yuan in the comparable period.Revenue declined 30% year over year to 1.46 billion yuan from 2.09 billion yuan, due to a change in the consolidation scope which excluded data from Tianjin Zhongxin Medicine.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0188","BK0164","BK0028","BK6506","T14.SI","BK0060","600329","BK6079"],"gpt_icon":0},{"id":"2531783809","title":"Tianjin Pharma's Attributable Profit Slips 3% in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2531783809","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531783809?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:44","pubTimestamp":1745923457,"startTime":"0","endTime":"0","summary":"Tianjin Pharma's Attributable Profit Slips 3% in Q1","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0188","600329","BK0060","BK0164","T14.SI","BK0028","BK6506","BK6079"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}